Search

Displaying results 2641 - 2650 of 8171 in total
  1. Drug

    Levonordefrin

    go.drugbank.com/drugs/DB06707
    ApprovedInvestigational

    Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.

  2. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  3. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with

  4. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577]. … It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].

  5. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.

  6. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.

  7. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    It is an alpha2-adrenergic agonist.

  8. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  9. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  10. Drug

    Flutemetamol (18F)

    go.drugbank.com/drugs/DB09151
    ApprovedInvestigational

    It is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029] … Flutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density.